Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH

Capital Fund Management S.A. acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 40,570 shares of the company’s stock, valued at approximately $931,000. Capital Fund Management S.A. owned approximately 0.09% of Amphastar Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Fuller & Thaler Asset Management Inc. lifted its stake in Amphastar Pharmaceuticals by 11.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company’s stock valued at $36,632,000 after acquiring an additional 130,672 shares during the period. Epoch Investment Partners Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 14.5% during the first quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company’s stock valued at $36,565,000 after purchasing an additional 160,034 shares during the last quarter. Geode Capital Management LLC lifted its position in Amphastar Pharmaceuticals by 1.9% during the second quarter. Geode Capital Management LLC now owns 973,237 shares of the company’s stock valued at $22,348,000 after purchasing an additional 18,161 shares during the period. Millennium Management LLC boosted its holdings in Amphastar Pharmaceuticals by 238.5% in the first quarter. Millennium Management LLC now owns 868,551 shares of the company’s stock worth $25,179,000 after purchasing an additional 611,995 shares during the last quarter. Finally, Systematic Financial Management LP grew its position in Amphastar Pharmaceuticals by 32.6% in the 1st quarter. Systematic Financial Management LP now owns 326,546 shares of the company’s stock worth $9,467,000 after purchasing an additional 80,198 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

AMPH has been the topic of several research analyst reports. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a report on Friday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a report on Monday. Needham & Company LLC cut their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Zacks Research lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Finally, Bank of America increased their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $31.20.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $26.77 on Friday. The firm’s 50 day simple moving average is $25.63 and its two-hundred day simple moving average is $25.61. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.12 and a quick ratio of 2.21. The company has a market capitalization of $1.23 billion, a P/E ratio of 11.85, a P/E/G ratio of 7.61 and a beta of 0.91. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $45.39.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million for the quarter, compared to the consensus estimate of $186.90 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current fiscal year.

Insider Activity

In other news, Director Floyd F. Petersen sold 16,679 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $26.49, for a total value of $441,826.71. Following the completion of the transaction, the director owned 75,531 shares of the company’s stock, valued at $2,000,816.19. This represents a 18.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $27.10, for a total value of $113,250.90. Following the sale, the director owned 35,183 shares of the company’s stock, valued at $953,459.30. This represents a 10.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 21,858 shares of company stock worth $581,313 over the last 90 days. Company insiders own 27.50% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.